BREAKING
CRITICAL95
APPROVAL · PRIMARY SOURCE
Novel Drug Approvals for 2026
The FDA approved Foundayo (orforglipron), a GLP-1-type peptide drug, on April 1, 2026, to help adults with obesity or overweight lose weight and keep it off when used with diet and exercise. The agency also cleared Awiqli (insulin icodec-abae), a long-acting insulin peptide, for blood sugar control in type 2 diabetes on March 26, 2026.
Analysis
Lilly's Foundayo (orforglipron) becomes the first oral GLP-1 approved for obesity, opening a pill-based weight-loss market and pressuring injectable franchises on convenience.
- FDA approved Foundayo (orforglipron) on 4/1/2026 for obesity/overweight with comorbidity
- Indication requires combination with reduced-calorie diet and increased physical activity
- FDA also cleared Awiqli (insulin icodec-abae) on 3/26/2026 for type 2 diabetes glycemic control
FDA Drug Approvals & Databases2d
Read